Wave Life Sciences Ltd. (WVE)

Wave Life Sciences Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Year	2023	2022	2021	2020	2019
Net Income	-57.51	-161.82	-122.25	-149.91	-193.64
Depreciation & Amortization	9.21	10.11	9.84	9.98	9.2
Share-Based Compensation	9.8	17.19	16.41	14.3	19.51
Other Operating Activities	19.08	6.73	7.01	9.65	-23.3
Operating Cash Flow	-19.43	-127.78	-88.99	-115.98	-188.23
Capital Expenditures	-1.12	-1.26	-0.56	-1.34	-3.92
Investing Cash Flow	-1.12	-1.26	-0.56	-1.34	-3.92
Share Issuance / Repurchase	132.53	52.92	55.83	154.54	164.4
Other Financing Activities	-	14.27	-	-	-
Financing Cash Flow	132.53	67.19	55.83	154.54	164.4
Exchange Rate Effect	-0.1	-0.21	-0.21	0.12	0.11
Net Cash Flow	111.89	-62.06	-33.93	37.34	-27.64
Free Cash Flow	-20.55	-129.04	-89.55	-117.32	-192.15
Free Cash Flow Margin	-18.13%	-3536.20%	-218.61%	-584.35%	-1202.21%
Free Cash Flow Per Share	-0.19	-1.64	-1.73	-2.99	-5.67

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).